Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04331015
Other study ID # JessaH-5-ORL
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 1, 2020
Est. completion date March 28, 2020

Study information

Verified date April 2020
Source Jessa Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To study the positive predictive value of Audiogene v.4.0 open source online machine learning tool in accurately predicting DFNA9 (DeaFNess autosomal dominant ninth) as top 3 gene loci in a large series of genetically confirmed c.151C>T,p.Pro51Ser (p.P51S) variant carriers in COCH (coagulation factor C Homology).


Description:

DFNA9 is an autosomal dominant hereditary adult-onset and progressive sensorineural hearing loss which is associated wit vestibular deterioration.

Today, artificial intelligence plays an increasing role in diagnosis of Mendelian hearing losses and in fitting of cochlear implants. An application of this kind is the open source program, Audiogene v4.0, which was elaborated by the Center for Bioinformatics and Computational Biology, University of Iowa City, Iowa, USA. The shape of the audiogram (audioprofile) is easily recognizable in many autosomal dominantly inherited hearing losses. Machine learning based software tools, such as Audiogene v4.0, which was originally developed for prioritizing loci for the Sanger sequencing, could help the clinicians in early diagnosis of DFNA9. This tool only need subjects' age and hearing thresholds (decibel hearing loss (dB HL)) at frequency range of 0.125 - 8 kHz (kiloHerz), left, right or binaural average in order to predict top 3 gene loci according to the data entered in the program.

Goal: to use auditory data of a large series of genetically confirmed p.P51S variant carriers causing DFNA9, which were previously collected for the genotype-phenotype correlation study which terminated recently.

All individual left and right sided hearing thresholds (ranging from 0.125 to 8kHz, with the exception of 1.5 kHz) as well as binaural averaged thresholds were run through Audiogene v4.0.

Descriptive statistics were assessed and statistical analysis was carried out to check for possible differences between age or hearing thresholds between the carrier group with accurate prediction against the carrier group with inaccurate prediction.


Recruitment information / eligibility

Status Completed
Enrollment 111
Est. completion date March 28, 2020
Est. primary completion date March 28, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- at least 18 years

- genetically confirmed c.151 C>T, p.Pro51Ser variant carrier in COCH gene

- not contra-indication for audiometric testing

Exclusion Criteria:

- <18 years

- no carrier status for c.151C>T, p.Pro51Ser

- no auditory data available

Study Design


Intervention

Diagnostic Test:
Pure tone audiometry
pure tone audiometry

Locations

Country Name City State
Belgium University of Antwerp Antwerpen
Belgium Jessa Hospital Hasselt Limburg

Sponsors (1)

Lead Sponsor Collaborator
Jessa Hospital

Country where clinical trial is conducted

Belgium, 

References & Publications (1)

Taylor KR, Deluca AP, Shearer AE, Hildebrand MS, Black-Ziegelbein EA, Anand VN, Sloan CM, Eppsteiner RW, Scheetz TE, Huygen PL, Smith RJ, Braun TA, Casavant TL. AudioGene: predicting hearing loss genotypes from phenotypes to guide genetic screening. Hum M — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary hearing threshold audiometry (pure tone) decibel hearing level (dB HL) left, right ear , binaural average 1 hour
Primary age years, age at time of audiometry 1 hour
Primary prediction gene locus top 3 gene loci as predicted by Audiogene v4.0 machine learning tool 1 hour
See also
  Status Clinical Trial Phase
Completed NCT00023036 - Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
Completed NCT03746613 - Clinal Evaluation of Navigation Based Functional Ear Surgery Using Image Guided and Robotically Assisted Techniques N/A
Recruiting NCT05568329 - Appreciation for Music Processed by Hearing Aids N/A
Withdrawn NCT05061758 - A Trial of LY3056480 in Patients With SNLH Phase 2
Completed NCT01434446 - The Effect of Sound Stimulation on Hearing Ability N/A
Completed NCT03212924 - Listening Effort in Cochlear Implant Users N/A
Recruiting NCT06053190 - Effects of Clear Speech on Listening Effort and Memory in Sentence Processing N/A
Completed NCT03718975 - Quality Control of CE-Certified Phonak Hearing Aids - 2018_28 N/A
Completed NCT06025097 - Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus. Early Phase 1
Recruiting NCT04102215 - The Efficacy of a Minimally Invasive Direct Cochlear Access Via the HEARO Procedure N/A
Recruiting NCT04108598 - The SeaSHeL National Prospective Cohort Study
Active, not recruiting NCT04750642 - Cochlear Implant With Dexamethasone Eluting Electrode Array N/A
Completed NCT04120116 - FX-322 in Adults With Stable Sensorineural Hearing Loss Phase 2
Recruiting NCT06223724 - Status Telemetry for Cochlear Implantations
Completed NCT02005822 - Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Phase 3
Suspended NCT02616172 - Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss Phase 1/Phase 2
Completed NCT02259595 - Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC Phase 1
Unknown status NCT01902914 - Effectiveness of P02 Digital Hearing Aids Phase 1/Phase 2
Completed NCT00589511 - Nucleus Freedom Cochlear Implant System Pediatric Post-approval Study N/A
Completed NCT03288753 - Comparison Between Neuro 1 and Neuro 2 Cochlear Implant Speech Processors N/A

External Links